Glenmark Pharmaceuticals announced on Monday that the country’s health regulator has given its generic Regadenoson injectable preliminary approval.
The regadenoson injection is given before a radiologic assessment of blood flow through the heart to check for coronary artery disease.
Glenmark Pharmaceuticals Inc, USA (Glenmark) received provisional clearance from the United States Food and Drug Administration (USFDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the company said in a statement. It’s the generic form of Astellas US Inc’s Lexiscan injection, 0.4 mg/5 mL (0.08 mg/mL), it said.
The Lexiscan Injection, 0.4 mg/5 mL (0.08 mg/mL) market had annual sales of roughly USD 659.9 million, according to IQVIATM sales statistics for the 12 month period ending November 2021.
According to the business, its current portfolio includes 172 medications approved for distribution in the United States and 47 abbreviated new drug applications (ANDAs) awaiting FDA clearance.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…